3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
76
Neoplasms
16
Prostatic Neoplasms, Castration-Resistant
14
Neoplasm Metastasis
9
Breast Neoplasms
9
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
5
Metastatic Castration-Resistant Prostate Cancer
5
Colorectal Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Metastatic Castration-resistant Prostate Cancer
3
Melanoma
3
Bulbo-Spinal Atrophy, X-Linked
3
mCRPC
2
Recurrence
2
Pancreatic Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castrate-Resistant Prostate Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Seizures
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
enzalutamide
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled